Is there an extra dose in a Mounjaro pen?

Why does a Mounjaro pen contain more liquid than four doses need?

Pharmaceutical manufacturers are required to include a small volume of overfill in injectable medicines. For the Mounjaro KwikPen, this accounts for the liquid needed to prime the needle before each injection, minor variation in the way the plunger seats, and the residual that inevitably stays in the needle and cannula after each dose is given. Without this buffer, the final dose in a pen could be under-delivered, a problem that matters greatly with a medicine where consistent dosing drives consistent results.

The pen's internal mechanism is calibrated to stop after four complete, measured injections. Once you reach the fourth dose, the plunger locks. You might look at the pen window afterward and see liquid remaining; that is by design, not waste or a counting error. Eli Lilly, who manufacture Mounjaro, set the fill volume to account for all the above variables. The NHS tirzepatide patient information page confirms each pen provides four weekly doses and that the pen should be disposed of after use even if it appears to contain liquid.

So when people ask why there is a dose left in a Mounjaro pen, the honest answer is: there is not one. There is overfill, the pharmaceutical industry's term for a deliberate, regulated margin that protects dose accuracy. It looks like a spare dose. It is not.

Is it safe to try to use the remaining liquid after the fourth dose?

This is one of the questions our prescribers hear regularly, and the answer is straightforward: no, and there are a few reasons why. First, the pen is physically designed to prevent a fifth injection, the plunger will not advance further once the mechanism locks. Second, even if someone tried to extract the residual liquid manually or use a separate needle, the volume remaining is variable and unmeasured; there is no way to know how much tirzepatide it contains or whether it would constitute anything close to a therapeutic amount.

Third, and perhaps most practically, your pen should go into a sharps container after your fourth dose. The Mounjaro Summary of Product Characteristics on the eMC is explicit that used pens must be disposed of safely after the fourth injection. Attempting workarounds with a spent pen is not a clinical grey area, it sits clearly outside the licensed use of the medicine.

If you are curious about whether your particular pen strength has any nuances worth knowing, the detailed answer to whether you can use the extra dose in a Mounjaro pen covers this in more depth. The short version: you cannot, and the pen is designed so that you do not need to.

What should you do when your pen runs out before your next order arrives?

Timing a repeat order takes a moment's thought. Most people order their next pen a few days before their fourth dose is due, particularly around bank holidays, or if your usual order day falls on a day when delivery timelines shift (a Monday order before a long weekend, for instance, is worth placing slightly earlier than usual). Running out mid-treatment is uncomfortable, and a small gap can occasionally reintroduce some of the initial side effects when you restart.

At nume, orders placed before 12pm on a working day go out the same day by DPD and arrive the next working day, which makes last-minute ordering more manageable than it sounds. But for uninterrupted treatment, forward-planning is still the better habit. You can read about how ordering works and what is included in our Mounjaro online ordering process, or explore the full picture of treatment on our Mounjaro treatment page.

If you do have a genuine gap and are unsure what to do, your prescriber is the right person to ask. Our aftercare team is available seven days a week for exactly this kind of practical question. Do not attempt to extend a used pen to bridge the gap, the overfill is not there for that purpose.

How does understanding the pen's design connect to your broader treatment?

Knowing how the pen works helps you use it with confidence rather than second-guessing each injection. The four-dose design, the dose-locking mechanism, the fixed injection volume, all of these are there so that your weekly injection is consistent from week one to week four of each pen, regardless of whether you inject into your abdomen, thigh or upper arm that particular morning.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed in the UK for weight management. Treatment begins at 2.5mg (a starting strength chosen to give your body time to adjust) and is titrated by your prescriber in line with how you are responding. Each pen strength in the UK range from 2.5mg up to 15mg follows the same four-dose format. If you are considering starting treatment or moving to a different strength, the cost and what it covers can be a reasonable practical concern; our weight-loss treatments page is the clearest place to see what is included.

Further reading: the detail on why the Mounjaro pen has extra dose liquid may answer follow-up questions, and for the broader picture of the 5mg Mounjaro pen specifically, that page covers the strength in full. Our clinical team oversees every prescription personally, a prescriber, not a process, signs off your treatment.